The hallmark of chronic myelocytic leukemia is the presence of the Philadelphia chromosome (Ph1). In recent studies, we obtained data that strongly suggested the involvement of an oncogene, c-abl, in this type of leukemia. This oncogene, normally located on chromosome 9, is translocated to chromosome 22 as a result of the Ph1 translocation. In addition, we identified a region on chromosome 22, the breakpoint cluster region (bcr), which contains the chromosomal breakpoint in all patients with chronic myelocytic leukemia who are positive for Ph1. Recent studies have suggested that the bcr is part of a gene that is truncated as a consequence of the Ph1 translocation. The deleted part of this gene could be replaced by c-abl sequences; to test this hypothesis we analyzed the RNA of five patients with chronic myelocytic leukemia. All five had chimeric bcr/c-abl messenger RNA, suggesting that the deleterious effects of this disease can be associated with an abnormal chimeric protein encoded by the bcr and the c-abl oncogene.
This article has been cited by other articles:
Fausel, C.
(2007). Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm
64: S9-S15
[Abstract][Full Text]
Signer, R. A. J., Montecino-Rodriguez, E., Witte, O. N., McLaughlin, J., Dorshkind, K.
(2007). Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia. Blood
110: 1831-1839
[Abstract][Full Text]
Tefferi, A., Dewald, G. W., Litzow, M. L., Cortes, J., Mauro, M. J., Talpaz, M., Kantarjian, H. M.
(2005). Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment. Mayo Clin Proc.
80: 390-402
[Abstract]
Wertheim, J. A., Perera, S. A., Hammer, D. A., Ren, R., Boettiger, D., Pear, W. S.
(2003). Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development. Blood
102: 2220-2228
[Abstract][Full Text]
Wong, S., McLaughlin, J., Cheng, D., Witte, O. N.
(2003). Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood
101: 4088-4097
[Abstract][Full Text]
Dunham, M. J., Badrane, H., Ferea, T., Adams, J., Brown, P. O., Rosenzweig, F., Botstein, D.
(2002). Characteristic genome rearrangements in experimental evolution of Saccharomycescerevisiae. Proc. Natl. Acad. Sci. USA
99: 16144-16149
[Abstract][Full Text]
Yao, R., Rich, S. A., Schneider, E.
(2002). Validation of Sixteen Leukemia and Lymphoma Cell Lines as Controls for Molecular Gene Rearrangement Assays. Clin. Chem.
48: 1344-1351
[Abstract][Full Text]
Laurent, E., Talpaz, M., Kantarjian, H., Kurzrock, R.
(2001). The BCR Gene and Philadelphia Chromosome-positive Leukemogenesis. Cancer Res.
61: 2343-2355
[Full Text]
Okuda, K., D'Andrea, A., Van Etten, R.A., Griffin, J.D.
(1998). The C-Terminus of c-Abl Is Required for Proliferation and Viability Signaling in a c-Abl/Erythropoietin Receptor Fusion Protein. Blood
92: 3848-3856
[Abstract][Full Text]
Haataja, L., Groffen, J., Heisterkamp, N.
(1997). Characterization of RAC3, a Novel Member of the Rho Family. J. Biol. Chem.
272: 20384-20388
[Abstract][Full Text]
Bishop, J.
(1987). The molecular genetics of cancer. Science
235: 305-311
[Abstract]
KURZROCK, R., BLICK, M. B., TALPAZ, M., VELASQUEZ, W. S., TRUJILLO, J. M., KOUTTAB, N. M., KLOETZER, W. S., ARLINGHAUS, R. B., GUTTERMAN, J. U.
(1986). Rearrangement in the Breakpoint Cluster Region and the Clinical Course in Philadelphia-Negative Chronic Myelogenous Leukemia. ANN INTERN MED
105: 673-679
[Abstract]
Groffen, J., Heisterkamp, N., Stam, K.
(1986). Oncogene Activation by Chromosomal Translocation in Chronic Myelocytic Leukemia. Cold Spring Harb Symp Quant Biol
51: 911-921
[Abstract]
